Showing results (111-120 of 330) with videos related to

Sort By:
Pageof 33
Nature Communications|February 6, 2025
Acute particulate matter exposure diminishes executive cognitive functioning after four hours regardless of inhalation pathwayThomas Faherty, Jane E Raymond, Gordon McFiggans, et al.
Advanced Materials (Deerfield Beach, Fla.)|September 16, 2024
Janus Swarm Metamaterials for Information Display, Memory, and EncryptionZenghao Zhang, Jeffery E Raymond, Joerg Lahann, et al.
Cancer Metastasis Reviews|December 31, 2013
Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?E Raymond, R García-Carbonero, B Wiedenmann, et al.
Family Planning Perspectives|July 1, 1992
To whom do inner-city minors talk about their pregnancies? Adolescents' communication with parents and parent surrogatesL S Zabin, M B Hirsch, M R Emerson, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2013
Mechanisms of action of tasquinimod on the tumour microenvironmentE Raymond, A Dalgleish, J-E Damber, et al.
Anti-Cancer Drugs|September 1, 1996
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cellsE Raymond, S Djelloul, C Buquet-Fagot, et al.
Macromolecules|May 20, 2014
Poly(carbonate-amide)s Derived from Bio-Based Resources: Poly(ferulic acid-co-tyrosine)Amandine Noel, Yannick P Borguet, Jeffery E Raymond, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 1991
Endocervical involvement by endometrial carcinoma on fractional curettage: a clinicopathological study of 37 casesC Caron, B Têtu, P Laberge, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 1989
Morphologic prognostic factors of malignant mixed müllerian tumor of the uterus: a clinicopathologic study of 58 casesE Gagné, B Têtu, L Blondeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimenT André, C Louvet, E Raymond, et al.
Pageof 33